Last reviewed · How we verify

TDM-105795, 0.0025%

Technoderma Medicines Inc. · Phase 2 active Small molecule

TDM-105795, 0.0025% is a Small molecule drug developed by Technoderma Medicines Inc.. It is currently in Phase 2 development.

At a glance

Generic nameTDM-105795, 0.0025%
SponsorTechnoderma Medicines Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about TDM-105795, 0.0025%

What is TDM-105795, 0.0025%?

TDM-105795, 0.0025% is a Small molecule drug developed by Technoderma Medicines Inc..

Who makes TDM-105795, 0.0025%?

TDM-105795, 0.0025% is developed by Technoderma Medicines Inc. (see full Technoderma Medicines Inc. pipeline at /company/technoderma-medicines-inc).

What development phase is TDM-105795, 0.0025% in?

TDM-105795, 0.0025% is in Phase 2.

Related